CN1100776C - 制备取代亚磺酰基杂环镁盐的方法 - Google Patents

制备取代亚磺酰基杂环镁盐的方法 Download PDF

Info

Publication number
CN1100776C
CN1100776C CN97194114A CN97194114A CN1100776C CN 1100776 C CN1100776 C CN 1100776C CN 97194114 A CN97194114 A CN 97194114A CN 97194114 A CN97194114 A CN 97194114A CN 1100776 C CN1100776 C CN 1100776C
Authority
CN
China
Prior art keywords
magnesium
methoxy
alkyl
alkoxy
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97194114A
Other languages
English (en)
Chinese (zh)
Other versions
CN1216989A (zh
Inventor
J·A·赫格贝里
P·伊安尼迪斯
A·马特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20402358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1100776(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra AB filed Critical Astra AB
Publication of CN1216989A publication Critical patent/CN1216989A/zh
Application granted granted Critical
Publication of CN1100776C publication Critical patent/CN1100776C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN97194114A 1996-04-26 1997-04-22 制备取代亚磺酰基杂环镁盐的方法 Expired - Fee Related CN1100776C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE96015987 1996-04-26
SE9601598A SE508669C2 (sv) 1996-04-26 1996-04-26 Nytt förfarande

Publications (2)

Publication Number Publication Date
CN1216989A CN1216989A (zh) 1999-05-19
CN1100776C true CN1100776C (zh) 2003-02-05

Family

ID=20402358

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97194114A Expired - Fee Related CN1100776C (zh) 1996-04-26 1997-04-22 制备取代亚磺酰基杂环镁盐的方法

Country Status (39)

Country Link
US (1) US6124464A (enExample)
EP (1) EP0897386B1 (enExample)
JP (1) JP4233115B2 (enExample)
KR (1) KR100468331B1 (enExample)
CN (1) CN1100776C (enExample)
AR (1) AR006640A1 (enExample)
AT (1) ATE222904T1 (enExample)
BR (1) BR9708829A (enExample)
CA (1) CA2251636C (enExample)
CZ (1) CZ295067B6 (enExample)
DE (1) DE69714987T2 (enExample)
DK (1) DK0897386T3 (enExample)
DZ (1) DZ2209A1 (enExample)
EE (1) EE03485B1 (enExample)
EG (1) EG23874A (enExample)
ES (1) ES2180981T3 (enExample)
HR (1) HRP970210B1 (enExample)
HU (1) HUP9901798A3 (enExample)
ID (1) ID16685A (enExample)
IL (1) IL126716A (enExample)
IS (1) IS1984B (enExample)
MA (1) MA24143A1 (enExample)
MY (1) MY119011A (enExample)
NO (1) NO318850B1 (enExample)
NZ (1) NZ332154A (enExample)
PL (1) PL188824B1 (enExample)
PT (1) PT897386E (enExample)
RS (1) RS49718B (enExample)
RU (1) RU2163238C2 (enExample)
SA (1) SA97170759B1 (enExample)
SE (1) SE508669C2 (enExample)
SI (1) SI0897386T1 (enExample)
SK (1) SK282752B6 (enExample)
TN (1) TNSN97068A1 (enExample)
TR (1) TR199802156T2 (enExample)
TW (1) TW420676B (enExample)
UA (1) UA51699C2 (enExample)
WO (1) WO1997041114A1 (enExample)
ZA (1) ZA973153B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
DE19843413C1 (de) 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
IL142629A0 (en) * 1998-11-18 2002-03-10 Astra Ab Improved chemical process and pharmaceutical formulation
CA2290893C (en) * 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
AU2001276721A1 (en) 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
WO2003063840A2 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
PT1487818E (pt) 2002-03-05 2007-07-18 Astrazeneca Ab Sais de alquilamónio de omeprazole e esomeprazole
TW200410955A (en) * 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
DE10234617B4 (de) * 2002-07-29 2013-04-04 Nycomed Gmbh Neues Salz von (S)-Pantoprazol
US20040235903A1 (en) * 2002-10-22 2004-11-25 Khanna Mahavir Singh Amorphous form of esomeprazole salts
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
EP1572680A2 (en) * 2002-12-19 2005-09-14 Eva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, known pantoprazole sodium hydrates, processes for their preparation.
MXPA05009183A (es) * 2003-02-28 2005-10-20 Ranbaxy Lab Ltd Polimorfos de s-omeprazol.
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
WO2005012289A1 (en) * 2003-07-17 2005-02-10 Altana Pharma Ag Novel salt of (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) * 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
ITMI20031813A1 (it) * 2003-09-23 2005-03-24 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procedimento per la preparazione di pantoprazolo e suoi sali.
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060141054A1 (en) 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
WO2007146341A2 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of pantoprazole magnesium salt
EP1947099A1 (en) * 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
EP2842953A1 (en) 2007-02-21 2015-03-04 Cipla Limited Process for the preparation of esomeprazole magnesium dihydrate
WO2009047775A2 (en) * 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
EP2426111A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
CN103467453A (zh) * 2013-09-13 2013-12-25 上海海虹实业(集团)巢湖今辰药业有限公司 一种奥美拉唑镁原料药制备方法
CN106397399A (zh) * 2015-07-29 2017-02-15 陕西合成药业股份有限公司 一种泮托拉唑镁的精制方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001977A1 (en) * 1993-07-09 1995-01-19 Astra Aktiebolag Magnesium omeprazole
WO1996001623A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag Multiple unit tableted dosage form i

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
IL76837A0 (en) * 1984-10-31 1986-02-28 Byk Gulden Lomberg Chem Fab Benzimidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing them
FI861772A7 (fi) * 1985-05-07 1986-11-08 Chemie Linz Ag Uudet tieno(2,3)imidatsolijohdokset ja menetelmä niiden valmistamiseksi.
US4851419A (en) * 1985-10-16 1989-07-25 Fisons Plc Certain 2-pyridinyl-phenylsulfinyl-benzoxazoles, the corresponding benzothiazoles or benzimidazoles having anti-inflammatory or gastric acid secretion inhibition activity
DD290192A5 (de) * 1986-11-13 1991-05-23 Eisai Co. Ltd,Jp Pyridinderivat mit antiulzeroeser wirkung
NZ234564A (en) * 1986-11-21 1991-04-26 Haessle Ab 1-substituted benzimidazoles and pharmaceutical compositions
WO1989000566A1 (fr) * 1987-07-21 1989-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Composes de pyridine et leurs utilisations en medecine
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
EP0644191A1 (en) * 1992-06-01 1995-03-22 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and medicinal use thereof
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5374730A (en) * 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001977A1 (en) * 1993-07-09 1995-01-19 Astra Aktiebolag Magnesium omeprazole
WO1996001623A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag Multiple unit tableted dosage form i

Also Published As

Publication number Publication date
WO1997041114A1 (en) 1997-11-06
CA2251636C (en) 2001-04-10
CZ295067B6 (cs) 2005-05-18
US6124464A (en) 2000-09-26
EE03485B1 (et) 2001-08-15
HK1016978A1 (en) 1999-11-12
RS49718B (sr) 2007-12-31
AU2719397A (en) 1997-11-19
YU44898A (sh) 1999-07-28
SI0897386T1 (en) 2002-12-31
ES2180981T3 (es) 2003-02-16
BR9708829A (pt) 1999-08-03
TW420676B (en) 2001-02-01
AU711345B2 (en) 1999-10-14
ZA973153B (en) 1997-10-27
NO984903D0 (no) 1998-10-21
TNSN97068A1 (fr) 1999-12-31
RU2163238C2 (ru) 2001-02-20
NZ332154A (en) 2002-03-01
EE9800363A (et) 1999-04-15
EG23874A (en) 2007-11-27
IS4872A (is) 1998-10-19
EP0897386A1 (en) 1999-02-24
EP0897386B1 (en) 2002-08-28
PT897386E (pt) 2002-12-31
PL329683A1 (en) 1999-04-12
KR20000065018A (ko) 2000-11-06
HUP9901798A2 (hu) 2000-04-28
HUP9901798A3 (en) 2003-02-28
SK282752B6 (sk) 2002-12-03
DE69714987T2 (de) 2003-04-30
SA97170759B1 (ar) 2006-09-25
JP4233115B2 (ja) 2009-03-04
SE508669C2 (sv) 1998-10-26
KR100468331B1 (ko) 2005-03-16
AR006640A1 (es) 1999-09-08
HRP970210B1 (en) 2002-06-30
CZ339898A3 (cs) 1999-03-17
MA24143A1 (fr) 1997-12-31
SE9601598D0 (sv) 1996-04-26
MY119011A (en) 2005-03-31
ID16685A (id) 1997-10-30
DE69714987D1 (de) 2002-10-02
SK140798A3 (en) 1999-04-13
UA51699C2 (uk) 2002-12-16
CN1216989A (zh) 1999-05-19
ATE222904T1 (de) 2002-09-15
DZ2209A1 (fr) 2002-12-03
NO984903L (no) 1998-10-21
SE9601598L (sv) 1997-10-27
CA2251636A1 (en) 1997-11-06
JP2000509067A (ja) 2000-07-18
PL188824B1 (pl) 2005-04-29
DK0897386T3 (da) 2002-10-28
NO318850B1 (no) 2005-05-18
TR199802156T2 (xx) 1999-02-22
HRP970210A2 (en) 1998-04-30
IL126716A0 (en) 1999-08-17
IS1984B (is) 2005-02-15
IL126716A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
CN1100776C (zh) 制备取代亚磺酰基杂环镁盐的方法
US7994332B2 (en) Process for producing crystal
IE59901B1 (en) Piperidine derivative, its preparation, and its use as medicament
US7638634B2 (en) Amorphous esomeprazole hydrate
KR20030042038A (ko) 온단세트론 히드로클로라이드의 신규한 결정 형태 및용매화물 형태와 이들의 제조 방법
AU711345C (en) Process for the preparation of a magnesium salt of a substituted sulphinyl heterocycle
MXPA98008790A (en) Process for the preparation of a magnesium salt of a heterocicle of sulfinyl sustitu
HK1016978B (en) Process for the preparation of a magnesium salt of a substituted sulphinyl heterocycle
JPH08239381A (ja) 安定なベンズイミダゾール誘導体金属塩の溶媒和物及びその製造法並びにそれを含有する抗潰瘍剤
CN119866340A (zh) 阿维巴坦钠盐的稳定的一水合物形式及其制备方法
KR20240174813A (ko) 크로메인 치환 벤즈이미다졸 유도체 및 염화아연을포함하는 공결정 고체 및 그 제조방법
ZA200303000B (en) Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ASTRAZENECA AB

Free format text: FORMER NAME: ASTRA AKTIEBOLAG

CP01 Change in the name or title of a patent holder

Address after: Swedish Sodertalje

Patentee after: Astrazeneca (Sweden) AB

Address before: Swedish Sodertalje

Patentee before: Astra Aktiebolag

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20030205

Termination date: 20160422

CF01 Termination of patent right due to non-payment of annual fee